Definitive-intent intensity-modulated radiation therapy for treatment of canine prostatic carcinoma: a multi-institutional retrospective study.
No standard of care is currently recognized for treatment of canine prostatic carcinoma (PC). This retrospective study assesses outcome following definitive-intent, intensity-modulated radiation therapy in dogs with PC. Medical records review was performed, including 18 patients from 4 institutions undergoing definitive-intent IMRT to treat PC. Diagnosis was incidental in 7/18 (39%) patients. Five dogs (28%) had evidence of metastasis to loco-regional lymph nodes at diagnosis. Seventeen patients received concurrent nonsteroidal anti-inflammatory drugs; 15/18 (83%) patients received maximally-tolerated dose (MTD) chemotherapy, with variable drugs and protocols employed. Total prescribed radiation dose ranged from 48-54 Gy (median 50 Gy) delivered as daily doses of 2.5-2.8 Gy. One patient was euthanized prior to completing radiotherapy. Acute toxicity was observed in nine patients; Grade 1-2 diarrhea was the most common toxicity observed. Suspected late toxicity (urethral stricture, ureteral stricture, and hindlimb edema) was observed in three patients. Median event-free survival following radiation therapy was 220 days, and median overall survival was 563 days. Local progression occurred in seven patients at a median of 241 days. Median overall survival was significantly longer in incidentally diagnosed dogs (581 days vs 220 days in symptomatic dogs, P = 0.042). Event-free survival was significantly longer in patients treated with MTD chemotherapy (241d vs 25d, P < 0.001), and significantly shorter in patients presenting with evidence of metastatic disease (109 days) vs those without (388 days, P = 0.008). These findings suggest that definitive-intent radiotherapy is a valuable treatment option for local control of canine PC with moderate risk of toxicity. This article is protected by copyright. All rights reserved.